European Medical Journal Diabetes (Oct 2013)

Is it Time to Transform Our Treatment Of Type 2 Diabetes

  • Michael Nauck,
  • Dídac Mauricio,
  • Anthony Barnett,
  • Tina Vilsbøll,
  • Samy Hadjadj,
  • Peter Rossing,
  • Edoardo Mannucci,
  • Harald Darius,
  • Chantal Mathieu

Journal volume & issue
Vol. 1, no. 1
pp. 22 – 29

Abstract

Read online

This meeting comprised two sessions: the morning session centred around glucagon-like peptide-1 receptor (GLP-1R) agonists and SGLT-2 inhibitors, a new class of glucose-lowering compounds, while the afternoon session focused on new results of cardiovascular safety studies with diabetes medications, with special attention to the SAVOR-TIMI trial of saxagliptin.

Keywords